The 3 references without contexts in paper M. Frolov Yu., V. Rogov A., М. Фролов Ю., В. Рогов А. (2016) “Фармакоэкономическое обоснование применения препарата Ленвима® (ленватиниб) при прогрессирующем дифференцированном раке щитовидной железы, рефрактерном к радиоактивному йоду, в Российской Федерации // PHARMACOECONOMIC STUDY OF LENVIMA (LENVATINIB) IN ADVANCED PROGRESSIVE RADIO IODINE REFRACTORY DIFFERENTIATED THYROID CANCER IN THE RUSSIAN FEDERATION” / spz:neicon:pharmacoeconomics:y:2016:i:1:p:24-32

16
Fordham B.A., Kerr C.L., de Freitas H.M. et al. Health state utility valuation in radioactive iodine-refractory differentiated thyroid cancer. Patient Prefer Adherence. 2015 Nov 3; 9: 1561-1572. DOI: 10.2147/PPA.S90425.
(check this in PDF content)
18
Kerr C., Fordham B., de Freitas H.M. et al. Health state utility valuation in radio-iodine refractory differentiated thyroid cancer (RRDTC). ISPOR 17th Annual European Congress. Amsterdam. 12 November 2014.
(check this in PDF content)
19
Matsui J., Minoshima Y., Tsuruoka A. et al. A:3614 Multi-targeted kinase inhibitor E7080 showed anti-tumor activity against medullary thyroid carcinoma and squamous thyroid carcinoma cell line based on RET and VEGFR2 tyrosine kinase inhibition. Proceedings of the 101st Annual Meeting of the American Association for Cancer Research. Washington, DC: American Association for Cancer Research. 2010.
(check this in PDF content)